Experienced in Pancreas Divisum

Miriam Cnop

Cp 618, 
Brussels, BRU, BE 
Experienced in Pancreas Divisum
Cp 618, 
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Miriam Cnop practices in Brussels, Belgium. Ms. Cnop is rated as an Experienced expert by MediFind in the treatment of Pancreas Divisum. Her top areas of expertise are Type 2 Diabetes (T2D), Microcephaly, Achalasia Microcephaly Syndrome, and Friedreich Ataxia.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Pancreas Divisum.

Gender
Female

Locations

Cp 618, Brussels, BRU 1070, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
Enrollment Status: Suspended
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drug: Verapamil SR
Study Phase: Phase 2
View 2 Less Clinical Trials

120 Total Publications

Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Journal: Science advances
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cnop's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile